Apollo Hospitals to Add 4,500 Beds With ₹3,500 Cr Capex

Expansion focus: North India and smaller cities

Apollo Hospitals Enterprises Ltd (AHEL) is preparing a fresh hospital expansion cycle that is weighted toward North India and deeper penetration in tier-2 and tier-3 markets. Managing Director Suneeta Reddy said the group reviewed its network and identified a need to build a stronger presence in northern markets and reinforce certain existing markets. The push comes as private healthcare demand rises with higher insurance penetration. The company believes the structural demand for quality healthcare is significant and requires more organised capacity. Apollo, which already operates at scale across major metros, is now looking to broaden reach beyond its traditional strongholds. The plan also reflects management’s intent to stay competitive as corporate hospital chains expand across India.

4,500-bed addition planned on a 9,000-bed base

Apollo currently has around 9,000 beds and plans to add at least 4,500 beds in the coming years, according to the managing director. The company is also positioning this capacity build-up as a response to the national gap in quality beds. Management highlighted that the private sector has about 1.5 lakh beds, and corporate hospitals like Apollo provide around 70,000 of them. With demand rising, Apollo has decided to expand in important markets where it sees clear need for more quality beds. The bed addition plan is expected to be spread across new hospitals, acquisitions, and expansions of existing facilities. Alongside metros, Apollo is targeting growth in state capitals and fast-growing urban centres.

New hospitals and near-term launches already lined up

Apollo has already opened a 225-bed hospital in Pune, with a stated plan to expand it to 450 beds within the next year. In Sarjapur, Bengaluru, the company has acquired the 180-bed Belenus Hospital, which is expected to be inaugurated early next year. This will be followed by the 250-bed Apollo Sonarpur Hospital in Kolkata. In the first quarter of the next financial year, Apollo said new facilities would open in Gachibowli (Hyderabad) and Gurgaon (NCR). Together, these projects are expected to add nearly 1,700 beds across the country. Apollo also said these projects would involve a capital investment of around ₹3,500 crore.

Brownfield expansions across key micro-markets

Beyond greenfield projects and acquisitions, Apollo is also expanding capacity through upgrades and expansions in established locations. The company said expansions are underway in Jubilee Hills, Worli, Seshadripuram and Mysore. These additions matter because brownfield projects typically leverage existing clinical talent pools, local brand equity, and referral networks. Management commentary also points to a strategy of strengthening its position in major metros where Apollo is already well covered, while selectively investing for leadership in markets such as Mumbai, NCR and Bengaluru. The mix of projects indicates Apollo is balancing large-city scale with the faster access benefits of bolt-on capacity.

Tier-2 and tier-3 push across multiple states

Apollo is stepping up presence in tier-2 and tier-3 cities such as Lucknow and Varanasi, and it also referenced existing operations in Madurai, Trichy, Karur, Karimnagar and Bilaspur. Management linked this push to expanding access to high-quality care and building out a broader footprint outside the top metros. The group’s CFO, Krishnan Akhileswaran, also spoke about building scalable asset-light models to expand access to high-quality care across tier-2 and tier-3 locations. The company’s strategy implies a mix of owned hospitals and partnership-led approaches, depending on the local economics and speed of rollout.

Capex and phased bed additions: multiple disclosed plans

Apollo’s expansion numbers have been discussed across management interviews and company updates, with several specific phasing disclosures. One management update stated Apollo would invest ₹6,000 crore over five years to add 3,500 beds across key urban centres, with focus areas including oncology, cardiology, neurosciences, and gastroenterology. Joint Managing Director Sangita Reddy said the expansion would add 3,512 beds via acquisitions, greenfield projects and brownfield developments. Under that two-phase plan, phase one, to be completed by FY26, involves ₹2,880 crore to add 1,737 beds in cities such as Pune, Kolkata, Hyderabad and Gurgaon. Phase two, over the following 3 to 4 years, targets 1,775 beds in Chennai, Varanasi, Mumbai and Lucknow with an additional ₹3,220 crore investment.

The CFO also referenced near-term execution, stating that in the coming 12 months Apollo expects to add around 1,500 beds, followed by another 2,000 beds over the next three years, and that capex of around ₹3,500 crore would be required.

Key capacity additions and locations at a glance

Growth expectations, occupancy cues, and return metrics

Apollo said existing hospitals are expected to grow at 12 to 13 percent annually over the next five years, while newer hospitals in these markets are projected to grow around 5 percent. It also said investments in these cities are delivering strong returns, with ROCE above 22 percent. Separately, an investor note cited occupancy at around 70% for 9MFY25 and indicated near-term growth may be supported by occupancy improvement and 6 to 7% ARPOB growth over the next few years. The same note referenced phased bed addition of 1,700+ over FY25 to FY27 to provide growth visibility while limiting drag on margins. These metrics frame how the company is thinking about ramp-up risk in new units versus steady performance at mature hospitals.

Market context: insurance penetration and demand for quality beds

Management linked the expansion cycle to the growing penetration of health insurance, which is widening access to quality healthcare. With the private sector at about 1.5 lakh beds, and corporate hospitals providing around 70,000 beds, Apollo’s view is that incremental quality capacity is needed in key markets. The company is also aligning expansions with high-burden specialties, citing the rising incidence of non-communicable diseases such as cancer and diabetes. This is relevant for capacity planning because specialty mix influences both clinical outcomes and the economics of a hospital ramp-up.

Clinical priorities and technology enablement

Apollo’s CFO emphasised that clinical outcomes and ethical care remain the core priorities and that financial decisions are aligned to clinical needs. He also said Apollo has a separate group working on clinical AI and that the company has been working with Microsoft and Google to enable patient care through AI-led support systems, including earlier diagnosis. While no financial impact was quantified in the disclosures, the commentary signals that Apollo views technology as part of standardising outcomes across an expanding network.

What investors and industry watchers will track next

The most immediate milestones are commissioning and scaling of the new hospitals and expansions already announced, including the next phase of bed additions across Pune, Bengaluru, Kolkata, Hyderabad and Gurgaon. The stated capex numbers and phased bed rollouts provide a clearer view of the pace at which Apollo intends to deploy capital. Execution will be monitored through occupancy ramp-up, specialty mix, and the extent to which mature hospitals sustain the 12 to 13 percent growth expectation cited by management. Apollo has also indicated it plans to share findings with government authorities to support nationwide NCD screening programmes, which could influence long-term demand patterns. For now, the central theme remains capacity creation across metros and targeted tier-2 and tier-3 markets, backed by disclosed multi-year investment plans.